CD70-targeted CAR-T/NK therapy: Rationale, advances, and future directions.
1/5 보강
Chimeric antigen receptor T and natural killer (CAR-T/NK) cells is a rapidly evolving cellular immunotherapy technology that has made great achievements in the treatment of hematologic diseases.
APA
Yan S, Zhu X, Xiao Y (2025). CD70-targeted CAR-T/NK therapy: Rationale, advances, and future directions.. Translational oncology, 62, 102555. https://doi.org/10.1016/j.tranon.2025.102555
MLA
Yan S, et al.. "CD70-targeted CAR-T/NK therapy: Rationale, advances, and future directions.." Translational oncology, vol. 62, 2025, pp. 102555.
PMID
41043320
Abstract
Chimeric antigen receptor T and natural killer (CAR-T/NK) cells is a rapidly evolving cellular immunotherapy technology that has made great achievements in the treatment of hematologic diseases. CD70, as a surface antigen expressed on tumor cells in a variety of hematologic malignancies, including acute myeloid leukemia, non-Hodgkin lymphoma, multiple myeloma, etc., and solid tumors such as renal cell carcinoma, osteosarcoma, and glioma, is a potential target for CAR-T/NK cells. Several preclinical studies and clinical trials on CAR-T/NK cells targeting CD70 are currently underway, bringing new hope for the treatment of CD70-positive tumors.
같은 제1저자의 인용 많은 논문 (5)
- The Prognostic Value of SERPINE1 in Clinical Outcomes in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.
- Artificial intelligence (AI)-based multi-organ contour quality assurance with uncertainty estimation for online adaptive radiotherapy (oART).
- Postoperative infectious complications in gastric and colorectal cancer patients: A multicenter prospective cohort study from China.
- A theranostic endoperoxide agent with targeted singlet oxygen release and concomitant fluorescence signals.
- ITGA4 Contributes to 5-Fluorouracil Resistance by Up-Regulating PI3K/AKT Signaling: Evidence from Network Pharmacology, Molecular Docking and Experimental Verification.